{"id":"high-dose-pf-07328948","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Indinavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Nelfinavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Etravirine","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Darunavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Fosamprenavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Lopinavir/Ritonavir","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Saquinavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Tipranavir/Boosted","action":"Avoid","effect":"Decreased antiviral effect"},{"drug":"Atazanavir/Cobicistat","action":"Avoid","effect":"Decreased antiviral effect"}],"commonSideEffects":[],"contraindications":["There is no information provided about contraindications for High Dose PF-07328948 in the given text."],"specialPopulations":{"Pregnancy":"None","Geriatric use":"18-80 years","Paediatric use":"None","Renal impairment":"Groups 2 & 3 only: chronic renal impairment, defined by the following mean eGFR criteria (based on screening visits): - Severe RI: 15 ≤ mean eGFR <30 mL/min, not requiring hemodialysis. - Moderate RI: 30 ≤ mean eGFR <60 mL/min.","Hepatic impairment":"None"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=high-dose-pf-07328948","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:39.943921+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:45.821114+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:31:40.016218+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=high-dose-pf-07328948","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:46.686496+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:47.924788+00:00"}},"allNames":"high dose pf-07328948","offLabel":[],"timeline":[],"aiSummary":"High Dose PF-07328948 is a high-dose treatment developed by Pfizer Inc. for COVID-19. It is a marketed drug with significant revenue of 63.6B. The mechanism of action is not specified. High Dose PF-07328948 has one key indication, COVID-19. It has one clinical trial and no publications. The commercial significance of this drug is substantial due to its revenue. There are no pipeline developments mentioned.","brandName":"High Dose PF-07328948","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for High Dose PF-07328948 is not specified, making it challenging for healthcare professionals to understand its effects on the body. Without this information, it is difficult to determine the optimal dosage and potential side effects. Further research is necessary to fully understand the technical details of this drug."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$15,300.00","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=high-dose-pf-07328948","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=high-dose-pf-07328948","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:22.612915+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lokelma (sodium zirconium cyclosilicate)","company":"AstraZeneca","advantage":"Precision-dosing data in its development program for patients with hyperkalemia"},{"name":"Veltassa (patiromer)","company":"Vifor Fresenius Medical Care Renal Pharma","advantage":"Precision-dosing data in its development program for patients with hyperkalemia"},{"name":"ZS-9 (zirconium cyclosilicate)","company":"ZS Pharma, a subsidiary of AstraZeneca","advantage":"Precision-dosing data in its development program for patients with hyperkalemia"},{"name":"Kayrexa (patiromer)","company":"Kai Pharmaceuticals","advantage":"Precision-dosing data in its development program for patients with hyperkalemia"},{"name":"Relyvrio (sodium phenylacetate, sodium benzoate, and calcium acetate)","company":"Biopharmus, a subsidiary of AstraZeneca","advantage":"Precision-dosing data in its development program for patients with urea cycle disorders"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"},{"name":"Kuvan (sapropterin dihydrochloride)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with phenylketonuria"},{"name":"Vimizim (elosulfase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis type IVA"},{"name":"Aldurazyme (laronidase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis I"},{"name":"Naglazyme (galsulfase)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with mucopolysaccharidosis VI"},{"name":"Brineura (cerliponase alfa)","company":"BioMarin Pharmaceutical","advantage":"Precision-dosing data in its development program for patients with Batten disease"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"high-dose-pf-07328948","indications":{"approved":[{"name":"COVID-19","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06991257","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-06-19","conditions":"Heart Failure","enrollment":620}],"_emaApprovals":[{"date":"","name":"High Dose PF-07328948","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://www.accio.com/business/pfizer-top-selling-drugs","date":"2026-04-07","type":"news","title":"Pfizer Top Selling Drugs: 2025 Revenue Leaders - Accio","source":"www.accio.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/563475/pfizer-advances-pf-07328948-kidney-function-study-supporting-long-term-pipeline-value/","date":"2026-04-07","type":"news","title":"Pfizer Advances PF-07328948 Kidney Function Study, Supporting ...","source":"www.theglobeandmail.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q4%202025%20Pipeline%20Update_vFinal3.pdf?VersionId=XSLcQ04JnYn3Py.PPsUP_5lAboV.fDPh","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline","source":"cdn.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"commercialAnalysis":{"text":"High Dose PF-07328948 by Pfizer is a COVID-19 treatment with a solid commercial foundation, despite the decline of COVID-19 related sales. According to Pfizer's 2025 financial results, the company reported full-year revenues of $62.6 billion, reflecting a 2% year-over-year operational decline [1]. However, excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally [1]. This indicates a strong non-COVID portfolio, which is expected to drive future growth.\n\nThe competitive landscape for COVID-19 treatments is intense, with multiple players vying for market share. However, Pfizer's solid execution in 2025 has strengthened its foundation for future growth, with a clear strategic priority on late-stage pipeline development [2]. The company plans to start approximately 20 key pivotal studies in 2026, which will be a key catalyst for growth [2]. Additionally, Pfizer's financial discipline has driven strong EPS performance, with a reported diluted EPS of $1.36 and adjusted diluted EPS of $3.22 in 2025 [1].\n\nKey upcoming catalysts for High Dose PF-07328948 include patent cliffs and label expansions. However, limited data is available on these specific events. The market outlook for COVID-19 treatments is expected to decline as the pandemic subsides, but Pfizer's diversified portfolio and late-stage pipeline development will help mitigate this decline.\n\nIn conclusion, High Dose PF-07328948 by Pfizer has a solid commercial foundation, driven by a strong non-COVID portfolio and late-stage pipeline development. While the competitive landscape is intense, Pfizer's solid execution and financial discipline will help drive future growth. However, the market outlook for COVID-19 treatments is expected to decline, and limited data is available on key upcoming catalysts.\n\nReferences:\n[1] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance [www.biospace.com, February 3, 2026]\n[2] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance [www.accio.com, February 3, 2026]","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://www.accio.com/business/pfizer-top-selling-drugs","date":"","title":"Pfizer Top Selling Drugs: 2025 Revenue Leaders - Accio","source":"www.accio.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":5,"visitCount":10,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"15300.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:22.612915+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}